Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

✍ Scribed by Todeschini, G; Tecchio, C; Meneghini, V; Pizzolo, G; Veneri, D; Zanotti, R; Ricetti, M M; Solero, P; Aprili, F; Perona, G

• Book ID: 110053741
• Publisher: Nature Publishing Group
• Year: 1998
• Tongue: English
• Weight: 92 KB
• Volume: 12
• Category: Article
• ISSN: 0887-6924
• DOI: 10.1038/sj.leu.2400912